BELA LASCHIVER: Open Payments
NPI 1497896286 · LIVINGSTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,037 in 72 payments from 16 companies in 2025. Trend: 2023 $1,980 · 2024 $2,065 · 2025 $2,037
Food & beverage: $2,037
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 9 | $450 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $348 |
| AstraZeneca Pharmaceuticals LP | 4 | $309 |
| Madrigal Pharmaceuticals | 8 | $217 |
| GlaxoSmithKline, LLC. | 10 | $165 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $94 |
| Novo Nordisk Inc | 5 | $94 |
| Novartis Pharmaceuticals Corporation | 5 | $87 |
| PFIZER INC. | 5 | $79 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $64 |
Products named: OTEZLA, REZDIFFRA, AIRSUPRA, TRELEGY ELLIPTA, JARDIANCE, REPATHA, BREZTRI, OFEV.
Industry payments across NJ — which companies pay providers there.
